Immunopathogenesis of human T cell lymphotropic virus type I-associated neurologic disease.
about
HTLV-1 tax specific CD8+ T cells express low levels of Tim-3 in HTLV-1 infection: implications for progression to neurological complicationsInternational Retrovirology Association brings together scientists and clinicians to bridge discoveries about human T-lymphotropic viruses from the laboratory to clinical trials.Role of Tax protein in human T-cell leukemia virus type-I leukemogenicityIncreased proviral load in HTLV-1-infected patients with rheumatoid arthritis or connective tissue diseaseQuantification of the virus-host interaction in human T lymphotropic virus I infection.How does HTLV-1 cause adult T-cell leukaemia/lymphoma (ATL)?Blood-brain barrier and retroviral infectionsHuman endogenous retroviruses and the nervous systemDynamic interaction between STLV-1 proviral load and T-cell response during chronic infection and after immunosuppression in non-human primatesAbnormally high levels of virus-infected IFN-gamma+ CCR4+ CD4+ CD25+ T cells in a retrovirus-associated neuroinflammatory disorder.Immunogenetics and the Pathological Mechanisms of Human T-Cell Leukemia VirusType 1- (HTLV-1-)Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP).HLA class I binding of HBZ determines outcome in HTLV-1 infection.Virus-induced dysfunction of CD4+CD25+ T cells in patients with HTLV-I-associated neuroimmunological disease.Reduced cell turnover in bovine leukemia virus-infected, persistently lymphocytotic cattleAscorbic acid has superior ex vivo antiproliferative, cell death-inducing and immunomodulatory effects over IFN-α in HTLV-1-associated myelopathyInfluence of HTLV-1 on the clinical, microbiologic and immunologic presentation of tuberculosis.HTLV-1 propels untransformed CD4 lymphocytes into the cell cycle while protecting CD8 cells from death.Inhibition of immune activation by a novel nuclear factor-kappa B inhibitor in HTLV-I-associated neurologic disease.Clinical manifestations in individuals with recent diagnosis of HTLV type I infection.Effect of TNF-α production inhibitors on the production of pro-inflammatory cytokines by peripheral blood mononuclear cells from HTLV-1-infected individualsEx vivo analysis of human T lymphotropic virus type 1-specific CD4+ cells by use of a major histocompatibility complex class II tetramer composed of a neurological disease-susceptibility allele and its immunodominant peptide.Immunopathogenesis of human T-cell leukemia virus type-1-associated myelopathy/tropical spastic paraparesis: recent perspectivesDysregulation of TGF-beta signaling and regulatory and effector T-cell function in virus-induced neuroinflammatory disease.Quantifying HTLV-I dynamics.Increased expression of OX40 is associated with progressive disease in patients with HTLV-1-associated myelopathy/tropical spastic paraparesisSevere loss of invariant NKT cells exhibiting anti-HTLV-1 activity in patients with HTLV-1-associated disorders.A crippling virus: diagnosing tropical spastic paraparesis.Neuroimmunological aspects of human T cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis.Multistability in a model for CTL response to HTLV-I infection and its implications to HAM/TSP development and prevention.How does HTLV-I persist despite a strong cell-mediated immune response?Are lipid disorders involved in the predominance of human T-lymphotropic virus-1 infections in women?High circulating frequencies of tumor necrosis factor alpha- and interleukin-2-secreting human T-lymphotropic virus type 1 (HTLV-1)-specific CD4+ T cells in patients with HTLV-1-associated neurological disease.Levels of serum chemokines discriminate clinical myelopathy associated with human T lymphotropic virus type 1 (HTLV-1)/tropical spastic paraparesis (HAM/TSP) disease from HTLV-1 carrier state.Role of neuronal interferon-gamma in the development of myelopathy in rats infected with human T-cell leukemia virus type 1.The elevated interferon gamma production is an important immunological marker in HAM/TSP pathogenesis.Human T-cell lymphotropic virus type I (HTLV-I) proviral DNA viral load among asymptomatic patients and patients with HTLV-I-associated myelopathy/tropical spastic paraparesis.Lower numbers of circulating Natural Killer T (NK T) cells in individuals with human T lymphotropic virus type 1 (HTLV-1) associated neurological disease.Amyotrophic lateral sclerosis presentation of a human T-lymphotropic virus type-1 myelopathy--insight into pathogenesis.HTLV-1 infection: role of CTL efficiency.HTLV-1-associated myelopathy/tropical spastic paraparesis.
P2860
Q24607794-125511B9-05C4-4F4B-AF8C-FD3E3CCCA812Q24796407-BFF2E76D-A23D-4B65-B266-1B1A7B722194Q24802464-C319CDB6-F040-40C7-9162-9CDCD17150E8Q24805302-8C4D1056-CE4C-4481-A6C4-DB2F0F5354F1Q25257600-D8FA4D67-51A3-41A0-9F0B-12999AD5D89BQ26785554-FD221185-D648-4E0E-AF11-F3905D76F30EQ26830903-55DE355C-80A9-4472-9BE3-E4FFD48A1175Q27012467-392310E4-AA15-4742-93F4-8EB8103FC826Q27347243-5EBA81DA-45CD-4B0B-ACE4-E5918C0A52A5Q33490596-2D56084D-2B11-4F10-B31F-B910166B5CDCQ33651831-25E8F066-3986-4469-A68E-E5B5AD251C28Q33707746-D5964538-BE8F-4B59-B6D9-8C0291C49F48Q33768325-91702A26-DDF1-4DD5-9C74-0CEC69A412FEQ34226486-6B7E0036-958E-4D44-9B62-1B82C1EB334DQ34359754-4CE92E7C-9225-454D-8256-967A038497D9Q34394609-522BD08E-520D-4484-99F5-29C9391FFC45Q34498932-B016991D-96A3-48B5-AD12-F6C322E63ED2Q34754386-24294262-F717-40EA-BA76-6FEE87BA6605Q34778829-4734A591-4FBA-4845-B804-57C3CBD3B1D0Q35663886-3F4DD1B5-757F-4A74-8A31-B50BD29312F7Q35891748-64BC0E24-2749-4397-AE17-511663C7FB59Q36422111-F7B8DD1A-2D93-44F7-8A12-23663886E60BQ36713538-0009782B-51CC-4C06-B760-09A1FAB5AE99Q36764476-0551DB7F-DDB8-40F8-950A-633028055D6DQ36859157-6A0191C0-55EB-4832-AE09-60256A9DDF49Q37381691-BB2F44A8-06ED-4394-8682-CA4CAAB2CFF6Q37948892-3AA48122-6A4A-4F0B-AF03-6BA87596D67BQ38128799-06CA479E-3DA0-4AA6-8828-7310040EA62BQ38546539-F7E6319A-FBD9-490C-A6C0-9B30C65BB747Q38882231-21F00BE0-35C7-497F-986A-355C03EF9D23Q38933560-C2B99FCB-3BCB-474A-B29D-0970D17831B3Q39028778-88F05493-A461-4751-89A1-D2AF02482565Q39035579-21F21ECA-B1CE-47AF-9064-6BEC54C1789BQ39255955-7AD25FBD-3123-457B-B476-CE6BCF33E582Q39263607-E887DEC8-5806-4A67-8DFA-65D42EEA6192Q39263618-B36CB47B-1551-40F1-820F-72A61AFBBB32Q39297216-C8C7BD74-D513-4314-873E-EF279B291924Q41082186-CAE60242-7D25-488F-89E4-BC50A10910C4Q42192501-C4207225-880C-43ED-B3F9-3E45309CDBBBQ45096240-98D89BDD-4A8B-4183-B381-5649355238FB
P2860
Immunopathogenesis of human T cell lymphotropic virus type I-associated neurologic disease.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Immunopathogenesis of human T ...... associated neurologic disease.
@ast
Immunopathogenesis of human T ...... associated neurologic disease.
@en
Immunopathogenesis of human T ...... associated neurologic disease.
@nl
type
label
Immunopathogenesis of human T ...... associated neurologic disease.
@ast
Immunopathogenesis of human T ...... associated neurologic disease.
@en
Immunopathogenesis of human T ...... associated neurologic disease.
@nl
prefLabel
Immunopathogenesis of human T ...... associated neurologic disease.
@ast
Immunopathogenesis of human T ...... associated neurologic disease.
@en
Immunopathogenesis of human T ...... associated neurologic disease.
@nl
P356
P1476
Immunopathogenesis of human T ...... associated neurologic disease.
@en
P2093
Steven Jacobson
P304
P356
10.1086/344269
P407
P478
186 Suppl 2
P577
2002-12-01T00:00:00Z